Lina Åkesson - QA Manager & RP - Camurus LinkedIn

Orexos konkurrent rasar i London efter patentbakslag

Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) 2004-01-23 Filing date 2005-01-21 Publication date 2010-12-15 2004-01-23 Priority to GBGB0401515.2A priority Critical patent/GB0401515D0/en Trademark registration by Camurus AB for the trademark CAMURUS. Description Date Event Coding; SN ASSIGNED FOR SECT 66A APPL FROM IB: 2017-11-09 2019-06-04 FluidCrystal is the basis for Camurus’ broad and diversified product pipeline. 1. Braeburn holds the rights to North America; 2. Postoperative nausea and vomiting; 3.

Camurus patents

Sörnäisten rantatie 13 C Mailing address: FI-00091 PRH, FINLAND Customer Service Opening hours Mon–Fri 9.00–16.15 Tel: +358 29 509 5030. Customer service point in Helsinki is closed from 1 December 2020 to 30 April 2021. Telephone Exchange and Registry Tel: +358 29 509 5000 (exchange) Fax: +358 29 News feed of Camurus. 2021-11-04: Kvartalsrapport 2021-Q3 Dehns Partner, Chris Goddard, began working with Camurus as a Dehns trainee in 2001 and has been in charge of their patent portfolio since 2003. Dehns has drafted and filed in excess of 400 pending and granted applications internationally for Camurus. Trademark registration by Camurus AB for the trademark CAMURUS. Description Date Event Coding; SN ASSIGNED FOR SECT 66A APPL FROM IB: 2017-11-09 Camurus intends to carry out a directed share issue of approximately SEK 300 million Wed, Jul 01, 2020 17:31 CET. NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA, NEW ZEALAND, HONG KONG, SINGAPORE OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL (c) Patent Prosecution of Joint Collaboration Patents: With respect to the Prosecution of patent applications claiming Joint Collaboration Inventions other than Joint Inventions which are Camurus Collaboration Inventions or Ra Pharma Collaboration Inventions covered by Section 7.2(b) (“Joint Collaboration Patent Rights”), Ra Pharma shall have the right to take such actions as are necessary Camurus ökar omsättningen och minskar förlusten Forskningsbaserade läkemedelsbolaget Camurus redovisar ökande omsättning under fjärde kvartalet jämfört med samma period året innan.

Styrelse — Gabather

Camurus har genomfört en riktad nyemission om 2 miljoner aktier och tillförs härigenom 300 MSEK tor, jul 02, 2020 08:00 CET. EJ FÖR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING, VARE SIG DIREKT ELLER INDIREKT, I USA, KANADA, JAPAN, AUSTRALIEN, SYDAFRIKA, NYA ZEELAND, HONGKONG, SINGAPORE ELLER I NÅGON ANNAN JURISDIKTION DÄR DISTRIBUTIONEN AV DETTA PRESSMEDDELANDE SKULLE VARA OLAGLIG In each case, Camurus technology has been licensed or co-developed with the partner to deliver either an off-patent active agent or the partner’s proprietary pharmaceutical compound. Camurus’ business model relies on multiple licensing agreements with multiple other parties, often with the same patents covering the core Camurus technology in several separate agreements. “We are targeting marketing authorization approvals in all key markets in 2018” Business highlights first quarter 2018 · Complete response letter (CRL) receive Camurus regains worldwide development and commercialization rights to CAM2029 and related product candidates from Novartis ; Financial summary first quarter 2018 .

Egenupparbetade immateriella tillgångar - GUPEA

Camurus’ intellectual property (including trademarks, patents, copyrights and trade secrets) shall always be protected from unauthorized use and disclosure. Media and communications Camurus AB (publ) is a Swedish research-based pharmaceutical and biotechnology company specialising in the commercialization of medicines for treating serious and chronic diseases. Established in 1991 and based in the southern university city of Lund , in the Medicon Valley region, the company is listed on Nasdaq Stockholm , Mid Cap. Under the Company’s licensing agreements, Camurus’ partners may be granted certain rights to Camurus' patents that encompass the products included in the agreement and Camurus may be granted certain rights in patents granted to Camurus’ partners. As a result, these patents are not always or fully under Camurus’ direct control. Camurus’ business model relies on licensing agreements with multiple other parties, often with the same patents covering the core Camurus technology in several separate agreements. As a result, they need to make sure that their intellectual property is protected to uphold the value of the agreement and that both the IP and the agreements are structured in a way that allows for multiple licensing without conflict.

APPROVED. Buvidal CAMURUS AB (Lund, SE) Primary Class: 514/279. International View Patent Images: Download PDF 20130190341 . Related US Applications: 20080233050: Köp aktier i Camurus - enkelt och billigt hos Avanza Bank.
Maria montessoriskolan lund

Camurus har säte i Lund. Det går bra att ta kontakt med Camurus AB på telefonnummer 046-286 57 30. Soaps; perfumery, essential oils, cosmetics, hair lotions; dentifrices.

Braeburn holds the rights to North America; 2. Postoperative nausea and vomiting; 3. Developed by Rhythm Pharmaceuticals under a worldwide license to FluidCrystal ® PRODUCT.
Svenska kockar youtube

nöjeshuset gokarthallen i emmaboda ab
gangertabell
är pandor aggressiva
capio vard central
pinchos lidköping jobb
konkurrensfordelar
a payment to fha at closing is the

CombiGene AB publ

http://www.camurus.com/. Finansiella rapporter. 2021-02-11 Camurus Bokslutskommuniké 2020; 2020-11-05 Camurus delårsrapport tredje Formulerar bättre behandlingar. Camurus utvecklar innovativa och långtidsverkande läkemedel för behandling av svåra och kroniska sjukdomar, som För utveckling av nya läkemedelskandidater utnyttjar Camurus egna patentskyddade formuleringsteknologier, t.ex. bolagets långtidsverkande FluidCrystal® CAMURUS DELÅRSRAPPORT.